NVLN - Novelion Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.81
-0.13 (-3.30%)
As of 3:08PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close3.94
Open3.76
Bid3.80 x 800
Ask3.90 x 900
Day's Range3.76 - 4.00
52 Week Range2.96 - 7.33
Volume32,625
Avg. Volume71,960
Market Cap71.828M
Beta2.08
PE Ratio (TTM)N/A
EPS (TTM)-7.40
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2013-06-28
1y Target Est5.75
Trade prices are not sourced from all markets
  • GlobeNewswire26 days ago

    Novelion Therapeutics Announces Next Phase of Operational Improvements

    Novelion Therapeutics Inc. (NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, today announced the next phase of operational improvements, following the January 2018 announcement of its initial cost reduction initiative.  The current phase of improvements reflects significant cost reduction efforts, which include a number of structural changes across nearly all business and staff functions. Interim Chief Executive Officer Jeff Hackman said, “The measures we announced today are consistent with our stated goals to improve operational efficiency and reduce cash operating expenses.  We intend to continue to take the necessary steps to help position our company for sustainable future growth.

  • Associated Presslast month

    Novelion Therapeutics: 2Q Earnings Snapshot

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of $1.67. Losses, adjusted for amortization costs and non-recurring costs, came to 59 cents per share. The retinal ...

  • GlobeNewswirelast month

    Novelion Therapeutics Reports Second Quarter 2018 Financial Results

    VANCOUVER, British Columbia, Aug. 07, 2018-- Novelion Therapeutics Inc., a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases, today ...

  • GlobeNewswire2 months ago

    Novelion Therapeutics Announces Marketing Authorization for MYALEPTA® (metreleptin) in the European Union to Treat Generalized and Partial Lipodystrophy

    MYALEPTA, a recombinant analog of human leptin, is the first and only licensed treatment in Europe indicated as an adjunct to diet as a replacement therapy to treat the complications of leptin deficiency in LD patients. The EC’s authorization follows the positive Committee for Medicinal Products for Human Use (CHMP) opinion on May 31, 2018. "The approval of MYALEPTA in the EU is a significant advancement for patients with generalized and partial lipodystrophy and a significant milestone for our company,” said Jeff Hackman, interim chief executive officer and chief operating officer.

  • GlobeNewswire3 months ago

    Novelion Therapeutics Appoints Mark Corrigan, M.D. as Executive Chair of the Board of Directors

    Novelion Therapeutics Inc. (NVLN) today announced that Mark Corrigan, M.D. has been appointed as Executive Chair of the Board of Directors. As Executive Chair, Dr. Corrigan will serve in a supervisory role to the Company’s management team and will continue to perform the traditional duties of Board Chair. In connection with Dr. Corrigan’s appointment, the Office of the CEO, which was comprised of Dr. Corrigan, Chief Operating Officer Jeff Hackman and former Chair Jason Aryeh, will be disbanded.

  • GlobeNewswire3 months ago

    Novelion Therapeutics Announces Presentation of Positive Metreleptin Data at American Diabetes Association Scientific Sessions

    Data Show Leptin Replacement Therapy Sustainably Decreased Weight Over Time in Patients with Low Baseline Leptin Levels Company plans to initiate Phase 2 proof of concept study in hypoleptinemic metabolic ...

  • GlobeNewswire3 months ago

    Novelion Therapeutics Announces Presentation of Positive Metreleptin Data at American Diabetes Association Scientific Sessions

    The study, titled “Efficacy of Metreleptin for Weight Loss in Overweight and Obese Adults With Low Leptin Levels,” was conducted in adults with low baseline leptin, defined as

  • Should You Invest In The Healthcare Sector And Novelion Therapeutics Inc (NASDAQ:NVLN)?
    Simply Wall St.3 months ago

    Should You Invest In The Healthcare Sector And Novelion Therapeutics Inc (NASDAQ:NVLN)?

    Novelion Therapeutics Inc (NASDAQ:NVLN), a US$76.13M small-cap, is a healthcare company operating in an industry, which faces key trends such as rising demand fuelled by an aging population and theRead More...

  • GlobeNewswire4 months ago

    MYALEPTA® (metreleptin) Receives Positive CHMP Opinion in Patients with Generalized and Partial Lipodystrophy

    Novelion Therapeutics Inc. (NVLN.TO), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that the European Medicines Agency`s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of marketing authorization, under exceptional circumstances, for MYALEPTA.

  • Analysts Expect Breakeven For Novelion Therapeutics Inc (NASDAQ:NVLN)
    Simply Wall St.4 months ago

    Analysts Expect Breakeven For Novelion Therapeutics Inc (NASDAQ:NVLN)

    Novelion Therapeutics Inc’s (NASDAQ:NVLN): Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. With theRead More...

  • Reuters4 months ago

    Former Aegerion sales rep charged with defrauding U.S. insurers

    A former Aegerion Pharmaceuticals Inc sales representative was arrested Tuesday on charges that he defrauded insurance companies into paying for the company's expensive cholesterol drug. Mark Moffett was charged with wire fraud and conspiracy in a criminal complaint unsealed in Massachusetts federal court. "Mark is an innocent man," Kenneth Cunniff, Moffett's lawyer, said in an email.

  • Associated Press4 months ago

    Novelion Therapeutics: 1Q Earnings Snapshot

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of $1.76. Losses, adjusted for non-recurring costs and stock option expense, came to 72 cents per share. The retinal ...

  • Novelion Therapeutics Inc (NASDAQ:NVLN): What Can We Expect From This High Growth Stock?
    Simply Wall St.5 months ago

    Novelion Therapeutics Inc (NASDAQ:NVLN): What Can We Expect From This High Growth Stock?

    In December 2017, Novelion Therapeutics Inc (NASDAQ:NVLN) announced its most recent earnings update, which suggested that losses became smaller relative to the prrior year’s level – great news for investorsRead More...

  • Does Novelion Therapeutics Inc’s (NASDAQ:NVLN) -139.66% Earnings Drop Reflect A Longer Term Trend?
    Simply Wall St.6 months ago

    Does Novelion Therapeutics Inc’s (NASDAQ:NVLN) -139.66% Earnings Drop Reflect A Longer Term Trend?

    Measuring Novelion Therapeutics Inc’s (NASDAQ:NVLN) track record of past performance is a useful exercise for investors. It enables us to understand whether or not the company has met or exceedRead More...

  • GlobeNewswire6 months ago

    Novelion Therapeutics Supports World Lipodystrophy Day

    VANCOUVER, British Columbia, March 31, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living ...

  • Associated Press6 months ago

    Novelion Therapeutics reports 4Q loss

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of $1.32. Losses, adjusted for non-recurring costs and stock option expense, came to 18 cents per share. The retinal ...

  • American City Business Journals7 months ago

    Doctor pleads guilty as part of Aegerion drug misbranding probe

    A pediatric cardiologist from Georgia has pleaded guilty to divulging information about his patients to Aegerion Pharmaceuticals in 2013, as the Cambridge-based company was looking for ways to boost sales of cholesterol drug Juxtapid by promoting it for off-label uses. During a hearing on Wednesday in Boston federal court, Eduardo Montaña pleaded guilty to violating the Health Insurance Portability and Accountability Act, or HIPAA. According to a court filing, Montaña admitted that he provided an Aegerion sales representative with a list of 280 young patients under his care who could potentially receive the drug.

  • Reuters7 months ago

    Doctor admits disclosing patient info to drugmaker Aegerion

    A Georgia pediatric cardiologist pleaded guilty on Wednesday to wrongfully disclosing information about his young patients to an Aegerion Pharmaceuticals Inc sales representative seeking to identify potential new users of an expensive cholesterol drug. Dr. Eduardo Montana, 55, entered his plea in federal court in Boston after Aegerion, a unit of Novelion Therapeutics Inc , agreed in September to pay $40.1 million to resolve U.S. investigations related to its marketing of the drug, Juxtapid.

  • GlobeNewswire7 months ago

    Novelion Therapeutics Observes Rare Disease Day

    Company Joins NORD, EURORDIS, CORD, The Global Genes Project and Others Worldwide in Supporting Awareness of Rare Diseases VANCOUVER, British Columbia, Feb. 28, 2018 (GLOBE NEWSWIRE) --  Novelion Therapeutics ...